Immunogenicity and Safety of a Novel MMR Vaccine (Live) (Freeze-dried): Results of a Phase II Clinical Trial
Journal Title: Journal of Clinical and Diagnostic Research - Year 2018, Vol 12, Issue 1
Abstract
ABSTRACT Introduction: This is the first study in Indian paediatric subjects to evaluate the novel Measles, Mumps and Rubella (MMR) vaccine developed by M/s Cadila Healthcare Limited, India, containing the Hoshino mumps strain. This phase II study was done as part of clinical development programme to evaluate the safety and immunogenicity of the novel vaccine in small cohort of target population before conducting the larger comparative phase III study. Aim: To evaluate the immunogenicity and safety of the singledose and multi-dose formulations of the novel vaccine. Materials and Methods: One hundred and twenty three healthy children 15-18 months of age were administered a single dose of the novel MMR vaccine from either the single-dose or the multi-dose formulation. Immunogenicity of the vaccine was assessed by measuring IgG antibodies against the measles, mumps and rubella viruses before and six weeks after the vaccination. Safety of the vaccine was assessed by recording adverse events during the six week study period. Results: The seroconversion rate for anti-measles and antimumps antibodies was 100% while that for anti-rubella antibodies was 98.9% after the MMR vaccination. There was no difference in the seroconversion rates in the subjects receiving the MMR vaccine either from the single-dose or the multi-dose formulation. The Geometric Mean Titre (GMT) of anti-measles, anti-mumps and anti-rubella antibodies was 3154.0 mIU/mL, 90.6 EU/mL and 141.7 IU/mL, respectively. The vaccine was well tolerated, 28 subjects (out of 123) reported 43 adverse events during the study (adverse event rate of 21.8%). The most common adverse event reported during the study was fever in 19 subjects (15.4%) followed by rash and rhinorrhoea in five subjects (4.1%) each. Conclusion: The results of this phase II clinical trial show that both the single-dose and the multi-dose formulation of the novel MMR vaccine are immunogenic and well tolerated by healthy paediatric subjects aged 15-18 months.
Authors and Affiliations
Rajesh Joshi, Neeta Hanumante, Uma Nayak, Shalaka Agarkhedkar, Paresh Thakkar, Jayesh Sanmukhani, Ravindra Mittal
Keywords
Related Articles
- EP ID EP523933
- DOI 10.7860/JCDR/2018/29855.11125
- Views 81
- Downloads 0
Delayed Presentation of Isolated Jejunal Perforation Following Accidental Trauma
Blunt abdominal trauma can injure any abdominal organs which had significant morbidity and mortality in paediatric age group. It can lead to duodenal, jejunal or rather any bowel perforation. Isolated jejunal perforation...
Comparative Analysis between Podography and Radiography in the Management of Idiopathic Clubfeet by Ponseti Technique
Introduction: Idiopathic clubfoot is one of the most common and oldest congenital foot anomalies. There are controversies regarding its optimum management protocol and methodologies to be employed for its functional outc...
Effectiveness and Safety of Heparinized Saline versus Normal Saline in Maintaining Patency of Peripheral Intravenous Locks in Neonates at a Tertiary Care Hospital
Introduction: Heparinized saline is usually used as a regular flush solution to prevent occlusion of peripheral intravenous locks in neonates but the risks associated with the use of heparin cannot be ignored in these pa...
Langerhans Cell Sarcoma of Thyroid: A Rare Differential for a Thyroid Swelling
Langerhans Cell Sarcoma (LCS) is a rare disease arising from antigen-presenting cells. The literature on LCS is largely limited to case series and only 67 such cases have been reported till date. We report a case of 27-y...
Antibiotic Resistance in Community Acquired Urinary Tract Infection in Children: Data from a Tertiary Center in Eastern India
ABSTRACT Introduction: Antibiotic resistance is an increasing global problem which hampers appropriate treatment of Urinary Tract Infection (UTI) in paediatric population, rendering the developing kidneys vulnerable for...